Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 14Terminated 6Unknown 5Recruiting 5Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5NET 3

Conditions

Neuroendocrine Tumors 3Pituitary Neoplasms 1Neoplasm Metastasis 1Growth Hormone-Secreting Pituitary Adenoma 1Carcinoid Tumor 1Acromegaly 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × lanreotide × Clear all
NCT04427787 2021-09-05

LOLA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
69 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02823691 2021-06-07

MetNET-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase EARLY_PHASE1 Unknown
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03083210 2019-05-20

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Samsung Medical Center

Phase 4 Unknown
28 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03439709 2018-03-01

MERGE

Samsung Medical Center

Phase 3 Unknown
90 enrolled
Endocrine

Acromegaly, Pituitary Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT01731925 2017-01-31

SUNLAND

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Unknown
44 enrolled
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡